Particularly, we revealed that CST6 showed a higher expression in breast cancer, pancreatic cancer, and prostate cancer, while the expression level of CST6 significantly decreased in liver cancer, lung cancer, melanoma, ovarian cancer, and renal cancer (Figure 2A). Here, CST6 is linked to breast carcinoma.